Hepatocellular carcinoma with osteoclast-like giant cells: Possibility of osteoclastogenesis by hepatocyte-derived cells

Pathology International

Volumn 53, Issue 7, 2003, Pages 450-456

  Ikeda, Tohru ^a   Seki, Sachiko ^a   Maki, Masahiko ^b   Noguchi, Norio ^a   Kawamura, Toru ^a   Arii, Shigeki ^a   Igari, Toru ^c   Koike, Morio ^a,c   Hirokawa, Katsuiku ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Osteoclastogenesis; Receptor activator of nuclear factor B; Receptor activator of nuclear factor B ligand

Indexed keywords

ACID PHOSPHATASE; ALBUMIN; CHLORDANE; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; RANK PROTEIN; TARTARIC ACID; UNCLASSIFIED DRUG;

AGED; ARTICLE; CASE REPORT; CELL PROLIFERATION; GIANT CELL; GIANT CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL; LIVER CELL CARCINOMA; MALE; MULTINUCLEAR CELL; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

AGED; ALBUMINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CARCINOSARCOMA; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; FATAL OUTCOME; GIANT CELLS; GLYCOPROTEINS; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0041731798     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2003.01503.x     Document Type: Article

References (26)

1. Goldring SR, Roelke MS, Petrison KK, Bhan AK. Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest 1987; 79: 483-91.
2. Lacey DL, Timms E, Tan H-L et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
3. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
4. Lum L, Wong BR, Joisen R et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999; 274: 13613-18.
5. Atkins GJ, Haynes DR, Graves SE et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000; 15: 640-49.
6. Huang L, Xu JK, Wood DJ, Zheng MH. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Pathol 2000; 156: 761-7.
7. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002; 117: 210-16.
8. Guccion JG, Enzinger FM. Malignant giant cell tumor of soft parts. An analysis of 32 cases. Cancer 1972; 29: 1518-29.
9. Alguacil-Garcia A, Unni KK, Goellner JR. Malignant giant cell tumor of soft parts. An ultrastructural study of four cases. Cancer 1977; 40: 244-53.
10. Munoz PA, Rao MS, Reddy JK. Osteoclast-like giant cell tumor of the liver. Cancer 1980; 46: 771-9.
11. Esmaili JH, Hafez GR, Warner TF. Anaplastic carcinoma of the thyroid with osteoclast-like giant cells. Cancer 1983; 52: 2122-8.
12. Kuwano H, Sonoda T, Hashimoto H, Enjoji M. Hepatocellular carcinoma with osteoclast-like giant cells. Cancer 1984; 54: 837-42.
13. Horie Y, Hori T, Hirayama C, Hashimoto K, Yumoto T, Tanikawa K. Osteoclast-like giant cell tumor of the liver. Acta Pathol Jpn 1987; 37: 1327-35.
14. McCluggage WG, Toner PG. Hepatocellular carcinoma with osteoclast-like giant cells. Histopathology 1993; 23: 187-9.
15. Hood DL, Bauer TW, Leibel SA, McMahon JT. Hepatic giant cell carcinoma. An ultrastructural and immunohistochemical study. Am J Clin Pathol 1989; 93: 111-16.
16. Berry B, MacFarlane J, Chen N. Osteoclastoma like anaplastic carcinoma of the thyroid. Diagnosis by fine needle aspiration cytology. Acta Cytol 1990; 34: 248-50.
17. Sasaki A, Yokoyama S, Nakayama I, Nakashima K, Kim Y-I, Kitano S. Sarcomatoid hepatocellular carcinoma with osteoclast-like giant cells: Case report and immunohistochemical observations. Pathol Int 1997; 47: 318-24.
18. Sakai Y, Kupelioglu AA, Yanagisawa A et al. Origin of giant cells in osteoclast-like giant cell tumors of the pancreas. Hum Pathol 2000; 31: 1223-9.
19. Ikeda T, Utsuyama M, Hirokawa K. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res 2001; 16: 1416-25.
20. Takahashi N, Yamaha H, Yoshiki S et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988; 122: 1373-82.
21. Athanasou NA, Quinn JM. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 1990; 43: 997-1003.
22. Quinn JM, Athanosou NA, McGee JO. Extracellular matrix receptor and platelet antigens on osteoclasts and foreign body giant cells. Histochemistry 1991; 96: 169-76.
23. Okada Y, Naka K, Kawamura K et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Laboratory Invest 1995; 72: 311-22.
24. Eriguchi N, Aoyagi S, Okuda K et al. Unusual liver carcinomas with sarcomatous features: analysis of four cases. Surg Today 2001; 31: 530-33.
25. Yamaguchi A, Katagiri T, Ikeda T et al. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myoginic differentiation in vitro. J Cell Biol 1991; 113: 681-7.
26. Itoh Y, Okanoue T, Ohnishi N et al. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of marcophage-colony stimulating factor. Liver 1999; 19: 97-103.